CSL Ltd
Company Profile
Business description
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.
Contact
655 Elizabeth Street
MelbourneVIC3000
AUST: +61 393891911
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
29,000
Stocks News & Analysis
stocks
Guzman Y Gomez’s outlook unchanged despite strong update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,840.40 | 28.60 | -0.32% |
| CAC 40 | 7,894.90 | 21.79 | 0.28% |
| DAX 40 | 25,248.34 | 50.27 | -0.20% |
| Dow JONES (US) | 51,888.87 | 267.39 | 0.52% |
| FTSE 100 | 10,819.57 | 94.71 | 0.88% |
| HKSE | 24,062.72 | 251.45 | -1.03% |
| NASDAQ | 26,480.39 | 212.47 | -0.80% |
| Nikkei 225 | 64,425.95 | 3,318.34 | -4.90% |
| NZX 50 Index | 13,832.80 | 72.41 | 0.53% |
| S&P 500 | 7,702.41 | 16.53 | -0.21% |
| S&P/ASX 200 | 8,719.70 | 8.20 | -0.09% |
| SSE Composite Index | 3,707.48 | 59.75 | -1.59% |